Versiti acquires Texas-based Cenetron Central Laboratories and Salus IRB to advance clinical trial capabilities

Milwaukee, Wis., – July 12, 2019 – Versiti, a national leader in blood health innovation, today announced the acquisition of Texas-based Cenetron Central Laboratories, and its subsidiary, Salus IRB, offering both organizations the opportunity to expand clinical trial services and expertise. Click here to Click Here to read more >>